GlobeNewswire: Diffusion Pharmaceuticals Inc. Contains the last 10 of 147 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:01:43ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/08/15/2725889/0/en/Diffusion-Pharmaceuticals-Stockholders-Approve-Merger-with-EIP-Pharma.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma2023-08-15T20:01:02Z<![CDATA[Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023]]>https://www.globenewswire.com/news-release/2023/03/30/2637499/0/en/EIP-Pharma-and-Diffusion-Pharmaceuticals-Announce-Merger-Agreement-to-Create-Leading-CNS-focused-Company-Treating-Neurodegenerative-Diseases.html?f=22&fvtc=4&fvtv=28020EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases2023-03-30T11:00:20Z<![CDATA[Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies]]>https://www.globenewswire.com/news-release/2022/12/16/2575337/0/en/Diffusion-Pharmaceuticals-Announces-Agreement-with-LifeSci-Special-Opportunities.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities2022-12-16T11:30:48Z<![CDATA[LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting]]>https://www.globenewswire.com/news-release/2022/12/05/2567200/0/en/Diffusion-Pharmaceuticals-Sends-Letter-to-Stockholders-Highlighting-Strength-of-Board-Leadership-and-Positive-Progress-in-Strategic-Review-Cautioning-Stockholders-Regarding-LifeSci.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing2022-12-05T11:30:53Z<![CDATA[CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today sent a letter to its stockholders. The letter highlights the strength, experience and quality of the Company’s board of directors as it continues to take steps to unlock stockholder value through a strategic review process. The letter also summarizes the value-destructive acquisition offer presented by LifeSci Capital on behalf of a purported client, the dismal track record of LifeSci Capital and its many affiliates in the biopharmaceutical space, and LifeSci-affiliated funds’ recent nomination of an unqualified dissident slate of nominees for election as directors at the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”).]]>Closing Dates of LifeSci-led MergersClosing Dates of LifeSci-led Mergershttps://www.globenewswire.com/news-release/2022/11/14/2555429/0/en/Diffusion-Pharmaceuticals-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update2022-11-14T21:01:28Z<![CDATA[CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the quarter ended September 30, 2022, and provided a business update.]]>https://www.globenewswire.com/news-release/2022/11/14/2554725/0/en/Diffusion-Pharmaceuticals-Sees-Significant-Progress-in-its-Strategic-Review-Process.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process 2022-11-14T11:30:55Z<![CDATA[Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process]]>https://www.globenewswire.com/news-release/2022/10/25/2540600/0/en/Diffusion-Pharmaceuticals-Announces-Strategic-Review-Process-to-Evaluate-Value-Enhancing-Alternatives-including-Opportunities-to-Better-Leverage-TSC.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC2022-10-25T10:30:10Z<![CDATA[]]>https://www.globenewswire.com/news-release/2022/08/11/2497250/0/en/Diffusion-Pharmaceuticals-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update2022-08-11T22:48:39Z<![CDATA[• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities• Expected Cash Runway into First Quarter of 2024]]>https://www.globenewswire.com/news-release/2022/07/26/2485795/0/en/Diffusion-Pharmaceuticals-to-Initiate-Phase-2-Trial-in-Patients-with-Glioblastoma-Multiforme-Incorporating-Innovative-Imaging-Methodology-to-Evaluate-Tumor-Oxygenation.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation2022-07-26T11:30:00Z<![CDATA[CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies to enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that after collaboration with the United States Food and Drug Administration (“FDA”) on the design of their Phase 2 clinical trial entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (“GBM”) Patients when Administered with Standard of Care (“SOC”)”. The trial will be designated Study 200-208. The Company expects to initiate the trial by the end of 2022 and anticipates dosing the first patient in the trial in the first quarter of 2023.]]>https://www.globenewswire.com/news-release/2022/06/23/2467890/0/en/Diffusion-Pharmaceuticals-Announces-Positive-Effects-in-Altitude-Trial.html?f=22&fvtc=4&fvtv=28020Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial2022-06-23T11:30:00Z<![CDATA[CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced positive effects from its second Oxygenation Trial, the Altitude Trial.]]>